American Heart Association/American College of Cardiology Foundation guide to warfarin therapy (Q34196283)

31 July 2017

American Heart Association/American College of Cardiology Foundation guide to warfarin therapy (English)

1 reference

31 July 2017

1 reference

4

Jonathan L Halperin

1 reference

31 July 2017

Jack Hirsh

1

1 reference

31 July 2017

Valentin Fuster

series ordinal

2

1 reference

31 July 2017

Jack Ansell

series ordinal

3

1 reference

31 July 2017

American Heart Association/American College of Cardiology Foundation

series ordinal

5

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

Journal of the American College of Cardiology

31 July 2017

1 reference

31 July 2017

41

1 reference

31 July 2017

1633-1652

1 reference

31 July 2017

9

1 reference

Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Normal and warfarin-resistant rat hepatocyte metabolism of vitamin K 2,3-epoxide: Evidence for multiple pathways of hydroxyvitamin K formation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Vitamin K Dependent Modifications of Glutamic Acid Residues in Prothrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Role of vitamin-K-dependent proteins in bone metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Congenital malformations associated with the administration of oral anticoagulants during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Maternal and fetal sequelae of anticoagulation during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Vitamin K and the oral anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Clinical Pharmacokinetics of Oral Anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Studies on the optical enantiomorphs of warfarin in man

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

The warfarin-sulfinpyrazone interaction: stereochemical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

The stereoselective interaction of warfarin and metronidazole in man

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Genetic control of anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Aging and the anticoagulant response to warfarin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Aging and warfarin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

"Resistance" to warfarin due to unrecognized vitamin K supplementation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Vitamin K deficiency from dietary vitamin K restriction in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

INFLUENCE OF FEVER UPON THE ACTION OF 3,3'-METHYLENE-BIS-(4-HYDROXYCOUMARIN) (DICUMAROL).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Effect of Sodium Dextrothyroxine in Patients Receiving Anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Hematologic perturbations associated with salicylate

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Acetaminophen and warfarin: undesirable synergy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Interaction of ibuprofen and warfarin on primary haemostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Effects of penicillin G on platelet aggregation, release, and adherence to collagen

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

The hemostatic defect produced by carbenicillin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: Danger of aspirin compared with dipyridamole

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Interactions of warfarin with drugs and food

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Drug interactions with coumarin anticoagulants. 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Drug interactions update: drugs, herbs, and oral anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Warfarin. From bedside to bench

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Decreased thrombin activity of fibrin clots prepared in cord plasma compared with adult plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Standardization of Laboratory Tests for Controlling Anticoagulant Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

An evaluation of chromogenic substrates in the control of oral anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Dosage and control of oral anticoagulants: an international collaborative survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Is the dose of warfarin prescribed by American physicians unnecessarily high?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalised ratios (INR)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Proficiency testing and standardization of prothrombin time: effect of thromboplastin, instrumentation, and plasma.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

The value of plasma calibrants in correcting coagulometer effects on international normalized ratios. An international multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

The correction of coagulometer effects on international normalized ratios: a multicentre evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

A comparison of lyophilized artificially depleted plasmas and lyophilized plasmas from patients receiving warfarin in correcting for coagulometer effects on international normalized ratios

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Comparison of two automated coagulometers and the manual tilt-tube method for the determination of prothrombin time

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Effect of automation on prothrombin time test in NEQAS surveys

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Automation and prothrombin time: a United Kingdom field study of two widely used coagulometers

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Failure of the International Normalized Ratio to generate consistent results within a local medical community

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Laboratory control of oral anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Monitoring warfarin therapy in patients with lupus anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Thrombosis in the Antiphospholipid-Antibody Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Factors affecting the maintenance dose of warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Risk factors for intracranial hemorrhage in outpatients taking warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Optimal oral anticoagulant therapy in patients with mechanical heart valves.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

A novel whole blood capillary technic for measuring the prothrombin time

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Bedside monitoring of warfarin therapy by a whole blood capillary coagulation monitor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Advances in the Monitoring of Oral Anticoagulation: Point-of-Care Testing, Patient Self-Monitoring, and Patient Self-Management

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Evaluation of the Ciba Corning Biotrack 512 coagulation monitor for the control of oral anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Practicability of patient self-testing of oral anticoagulant therapy by the international normalized ratio (INR) using a portable whole blood monitor. A pilot investigation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Patient Self-Management of Oral Anticoagulation Guided by Capillary (Fingerstick) Whole Blood Prothrombin Times

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Long-term patient self-management of oral anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Computer assisted management of warfarin treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Prospective comparative study of computer programs used for management of warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Temporary discontinuation of warfarin therapy: changes in the international normalized ratio

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Comparing different routes and doses of phytonadione for reversing excessive anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Plasma disposition of vitamin K1 in relation to anticoagulant poisoning

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Managing oral anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Trial of different intensities of anticoagulation in patients with prosthetic heart valves.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Hemorrhagic complications of anticoagulant treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Management of anticoagulation before and after elective surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Outcome of pregnancy in women with valve prostheses

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Management of anticoagulants during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Low molecular weight heparin after mechanical heart valve replacement.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Is warfarin sodium contraindicated in the lactating mother?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Prophylaxis of thromboembolism in pregnancy: an alternative

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Warfarin necrosis of the skin and subcutaneous tissue of the male external genitalia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Necrosis of skin induced by coumarin in a patient deficient in protein S

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Prevention of venous thrombosis and pulmonary embolism in injured patients. A trial of anticoagulant prophylaxis with phenindione in middle-aged and elderly patients with fractured necks of femur

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Reduction of factor VII coagulant activity (VIIC), a risk factor for ischaemic heart disease, by fixed dose warfarin: a double blind crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Prevention of venous thrombosis with minidose warfarin after joint replacement.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Efficacy of fixed minidose warfarin prophylaxis in total hip replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Clinical problem-solving: diagnosing spousal abuse

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

How we diagnose and treat deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous Thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Antithrombotic agents in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Long-term anticoagulant therapy after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Oral anticoagulant in patients surviving myocardial infarction. A new approach to old data

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

The effect of warfarin on mortality and reinfarction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Reactivation of unstable angina after the discontinuation of heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Combination therapy with tirofiban and enoxaparin in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Dise

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Prosthetic heart valves

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Stroke Prevention in Atrial Fibrillation Study. Final results

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Canadian atrial fibrillation anticoaguiation (CAFA) study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Stroke prevention in nonvalvular atrial fibrillation: A review of prospective randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Co

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Antithrombotic therapy for cerebrovascular disorders. An update

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

The natural history of idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Stroke in patients with heart failure and reduced left ventricular ejection fraction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900416-9

7 January 2021

10.1016/S0735-1097(03)00416-9

Identifiers

DOI

1 reference

31 July 2017

1 reference